The role of metabolic reprogramming in T cell fate and function.
Nikolaos Patsoukis(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Kankana Bardhan(Seres Therapeutics (United States)), Christoph Herbel(Beth Israel Deaconess Medical Center), Lequn Li(Beth Israel Deaconess Medical Center), Pankaj Seth(Janssen (United States)), Jessica D. Weaver(Beth Israel Deaconess Medical Center)
PubMed
January 1, 2016
Cited by 43
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859